Skip Navigation Archive: U.S. Department of Health and Human Services www.hhs.gov
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

No Differences Found Between Medicare Fee-for-Service and HMO Patients for Heart Attack Followup Care but Effective Drugs Are Under-Prescribed for Both

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Press Release Date: July 13, 2001

Type of Medicare coverage may make no difference when it comes to the likelihood that elderly beneficiaries being seen by doctors for post heart-attack care will receive effective treatment, according to a new study supported by the U.S. Agency for Healthcare Research and Quality. Findings reported by a team of Harvard Medical School researchers indicate that patients in Medicare's traditional fee-for-service program were approximately just as likely as those in Medicare HMOs to be prescribed three drugs proven effective for improving the survival of older patients who have had heart attacks—beta blockers, which slow the heart rate and prevent abnormal heart rhythms; ACE inhibitors, which improve heart function; or cholesterol-lowering drugs, which reduce atherosclerosis.

Furthermore, although the study was unable to say what percentages of the patients should have received these medications, the usage rates of beta blockers and cholesterol-lowering drugs were low—about a third of the patients were prescribed them. This is about the same percentage that were given calcium channel blockers, which are less effective but continue to be prescribed. Estimates from the National Health and Nutrition Examination Survey suggest that at least 53 percent of men and 64 percent of women age 65 and older with coronary artery disease have low-density lipoprotein levels that would benefit from cholesterol-lowering therapy, and randomized trials of beta blockers that included elderly heart attack patients indicate that elderly patients may benefit more than younger patients from these drugs. These low rates indicate that there are significant opportunities for improving the quality of post-acute myocardial infarction care for both Medicare fee-for-service and HMO patients.

The researchers also found no major differences in the percentages of patients in both types of Medicare plans who were told by their doctors to exercise more and/or quit smoking. The only significant difference was that the traditional Medicare patients were referred more often to cardiac rehabilitation programs, possibly because of professional fees for this service under fee-for-service care.

When the researchers studied elderly Medicare patients as a whole, they found several unexplained regional differences among patients who lived in the Northeast, California or Florida. Those in northeastern states were prescribed beta blockers and ACE inhibitors more often than were Medicare patients in California or Florida, but they were less likely to be given drugs to lower their cholesterol levels. According to the study's leaders, John Z. Ayanian, M.D., and Barbara J. McNeil, M.D., Ph.D., these variations suggest the need for educational efforts tailored to the geographic area.

The findings are based on interviews conducted in 1996 and 1997 of roughly 1,000 Medicare patients aged 65 and older approximately 18 months after discharge from a hospital for heart attack.

For more information, see "Quality of Ambulatory Care After Myocardial Infarction Among Patients by Type of Insurance and Region," in the July 13, 2001 issue of the American Journal of Medicine by Mary Seddon, Dr. Ayanian, Dr. McNeil, and colleagues.

Note to Editors: For interviews of Dr. Ayanian or Dr. McNeil, call John Lacey of the Harvard Medical School Public Affairs Office at (617) 432-0441.

For more information, please contact Bob Isquith, (301) 427-1539 (RIsquith@ahrq.gov).


 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care